Mr Alistair Taylor

Non-Executive Chairman

Mr Taylor is formerly Executive Chairman of UK listed Lombard Medical Technologies plc and has 45 years experience in the healthcare industry, ten years in pharmaceuticals and 35 years in medical devices.

He was Chief Executive Officer of Biocompatibles International plc from 1994 to 1998 and during this period the company progressed from a technology-based start up company, through flotation to a FTSE 250 company. Prior to this, Mr Taylor was Chief Executive Officer of Schneider Inc., the interventional cardiology/radiology division of Pfizer Inc., an orgainisation that the had acquired on behalf of Pfizer for $16 million in 1984. This division was subsequently sold by Pfizer Inc. for $2.1 billion in 1998.

He is also Non-Executive Chairman of Nightingale-EOS Limited, Executive Chairman of Arterius Limited and a Non-Executive Director of Cellnovo Limited and Giltech Lmited.

Committees: Audit, Nomination and Remuneration Committees

Mr A D (Sandy) Morrison

Non-Executive Director

Mr Morrison has a BSc (Hons) in applied chemistry (Strathclyde) and has over 20 years experience in general and international management, global supply chain management and R&D. He was Chief Executive Officer of Lipton Ltd, the global tea sourcing organization for Unilever with operations in six countries for five years from 2000 to 2006. During Mr Morrison’s period as CEO, substantial operational & financial improvements were made to the Unilever global tea supply chain and he also played a significant part in addressing issues in the international tea trade.

In the immediate years prior to 2000, Mr Morrison had senior international food & beverage roles for Unilever outside the UK, in the supply chain and in R&D, both at the Rotterdam head office and in the Unilever food and beverage subsidiary in Australia.

Committees: Chairman of the Audit Committee

Dr Peter Blower

Non-Executive Director

Dr Blower has over 30 years experience in medicinal research and development with a strong background in the field of neuroscience. Dr Blower joined Beecham Research Laboratories in 1969 and rose to the position of Director of New Neuroscience products in 1996 before leaving in 2000 to form his own consultancy company.

He has been elected to Fellowship of the Royal Society of Medicine and the Institute of Biology and has authored over 50 scientific publications. He has a M.I.Biol from the Institute of Biology (1972), a PhD in Pharmacology from the University of Aston (1977) and a DSc from the University of East London (1997).

Committees: Chairman of the Remuneration and Nomination Committee

Mr Tim Sharpington

CEO

Mr Sharpington has nearly 20 years’ experience in the life sciences sector with various biotechnology and pharmaceutical service companies in Europe and the USA. He has broad experience across drug development, in-licensing, M&A as well as fund raisings.

In 2002, Mr Sharpington was appointed as Development Director at Arakis Ltd, a UK based inflammatory and CNS focused company where he led the development of four projects from concept to Phase II, participated in the licensing of its lead product to Novartis and also had a pivotal role in the successful sale of Arakis to Sosei in 2005 for £107 million.

After leaving Arakis Mr Sharpington founded and became CEO of Serentis Limited in 2006 where he led a £15 million venture capital fundraising and the development of two dermatology products to Phase II.

Mr Sharpington is also a Non-Executive Director of Clinical Force Limited, a clinical trial software and service company.

 

Committees:

Mr Roger Hickling

R & D Director

Mr Hickling has a BSc in Chemistry from Kings College, University of London and over 30 years experience in pharmaceutical R & D. This includes management of development portfolios and projects from preclinical through to Phase IV covering a range of disease areas. In addition, Mr Hickling has extensive experience in international regulatory affairs, including clinical trials and marketing applications.

Between 1976 and 1998 Mr Hickling worked at SmithKline Beecham where he oversaw both in-house and partnered early stange development projects.

Mr Hickling held a variety of positions at several phamrmaceutical companies between 1998 and 2009 including  Alizyme Therapeutics plc. He was appointed to the Board of Alizyme as R & D Director in 2006 with responsibility for R & D strategy development, all R & D operations and staff.

Committees: